NCT07221500Phase 2Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Study sponsor: Nurix Therapeutics, Inc. · NRIX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-01Estimated
Enrollment · participants100Estimated
Source updated2026-11-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective response rate as determined by an Independent Review Committee (IRC). After: Measure: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC).

Check registry source